TruScreen Group Restricted (NZX/ASX:TRU) is happy to announce the preliminary publication, on 25 July 2024, of a examine titled “Past Custom: Investigating TruScreen’s Efficiency Versus Pap Smear in Cervical Most cancers Detection” on Analysis Sq.1 Hyperlink. The preliminary publication is topic to see evaluation.
Highlights
- 507 girls examined from 2021-2022, outcomes printed in July 2024
- Excessive Sensitivity and Specificity: TruScreen demonstrated a sensitivity of 83.3% and a specificity of 95% for detecting cervical lesions (neoplasms), in comparison with 66.7% and 98.2% for Pap smear, respectively1.
- Actual-Time Outcomes: The TruScreen system gives fast screening outcomes, eliminating the necessity for laboratory gear and pathology workers.
- Sensible and Dependable: The examine confirmed that TruScreen is a sensible and dependable screening instrument, appropriate to be used in numerous healthcare settings.
The authors concluded that TruScreen “represents a dependable, sensible screening instrument for cervical neoplasms” and that their outcomes “present an evidence-based method for policymakers when choosing the optimum cervical most cancers screening technique in international locations with out a longtime nationwide screening program.”
This examine reinforces TruScreen’s dedication to offering modern and accessible healthcare options. The constructive outcomes validate TruScreen’s know-how and opens new alternatives within the world healthcare market.
For extra data, please go to our web site at www.truscreen.com.
Click on right here for the total ASX Launch
This text contains content material from Truscreen, licensed for the aim of publishing on Investing Information Australia. This text doesn’t represent monetary product recommendation. It’s your duty to carry out correct due diligence earlier than appearing upon any data supplied right here. Please seek advice from our full disclaimer right here.
